Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in the EU / 2025-521293-34-00
Authorised, recruitment ended Phase II

A Seamless Phase 2a/2b, Randomized, Double-Blind, Placebo- and Active-Controlled, Multiple-Arm, Multiple-Stage, Adaptive Study Evaluating the Efficacy and Safety of LAD191 in Adults With Moderate-to-Severe Hidradenitis Suppurativa

2025-521293-34-00 · tracked via the Priya Life Science EU tracker
Sponsor
Almirall S.A
Sponsor type
Pharmaceutical company
Therapeutic area
Skin and Connective Tissue Diseases
Decision date
03/11/2025
Enrollment target
128
Sites
Germany, Italy, Ireland, Poland, Spain, France

Condition studied

Moderate-to-severe hidradenitis suppurativa

Investigational medicinal product(s)

LAD191LAD191 placeboSODIUM CHLORIDEADALIMUMAB

Eligibility

Age group
18-64 years
Sex
Female, Male

Primary endpoint

Proportion of participants achieving HiSCR 50, Safety endpoint: Frequency and severity of treatment-emergent AEs, SAEs, AEs leading to discontinuation, and AESIs, Safety endpoint: Local tolerance, vital signs, ECGs, and clinical laboratory parameters

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-521293-34-00 on CTIS ↗ ← All trials in the EU